X-ray-morphologic and radiomorphometric results in patients with primary hyperparathyroidism (Poster)

1992 ◽  
pp. 389-390
Author(s):  
K.P. Schröder ◽  
P. Dietel ◽  
H.J. Heberling ◽  
D. Lohmann
Keyword(s):  
Primary Hyperparathyroidism ◽  
X Ray

CTRP3 is Significantly Decreased in Patients with Primary Hyperparathyroidism and Closely Related with Osteoporosis

2019 ◽  
Vol 128 (03) ◽  
pp. 152-157
Author(s):  
Derya Demirtas ◽  
Fettah Acıbucu ◽  
Filiz Alkan Baylan ◽  
Erdinc Gulumsek ◽  
Tayyibe Saler
Keyword(s):  
Primary Hyperparathyroidism ◽  
Serum Levels ◽  
Dual Energy ◽  
Control Group ◽  
Mineral Density ◽  
Urine Calcium ◽  
X Ray ◽  
Complement C1q ◽  
Necrosis Factor

Abstract Background Adipokines derived from adipocytes are one of the important factors that act as circulating regulators of bone metabolism. Complement C1q/tumor necrosis factor-related protein-3 (CTRP3), a paralog of adiponectin, is are member of the CTRP superfamily. The aim of this study was to investigate the role of serum CTRP3 in the development of osteoporosis in patients with primary hyperparathyroidism. Methods This study included 53 patients with diagnosed primary hyperparathyroidism and 30 healthy controls. Laboratory tests for the diagnosis of primary hyperparathyroidism and serum levels of CTRP3 measured for all patients. Bone mineral density was obtained on lumbar spine 1 and 4 by dual energy X-ray absorptiometry. Results Serum CTRP3 levels were lower in patients with primary hyperparathyroidism than in the control group (p<0.001). In addition, primary hyperparathyroidism patients are were divided into two groups as, with and without osteoporosis; the levels of CTRP3 were lower in patients with osteoporosis than in patients without osteoporosis (p=0.004). In logistic regression analysis, only CTRP3 levels independently determined the patients to be osteoporosis (p<0.05). According to this analysis, decreased CTRP3 (per 1 ng/mL) levels were found to increase the risk of patients for osteoporosis by 6.9%. When the CTRP3 cut-off values were taken as 30 ng/mL, it determined osteoporosis with 76.4% sensitivity and 73.2% specificity. CTRP3 and urine calcium levels were independently associated with T score in dual energy X-ray absorptiometry. Conclusions CTRP3 levels were significantly decreased in patients with primary hyperparathyroidism, and it is also related to osteoporosis.

scholarly journals Evaluation of Bone Mineral Density in Subjects with Primary Hyperparathyroidism by Dual Energy X-Ray Absorptiometry

2018 ◽  
Vol 20 (2) ◽  
pp. 129
Author(s):  
Rezwana Haque ◽  
Raihan Hussain ◽  
Shamim MF Begum
Keyword(s):  
Bone Loss ◽  
Femoral Neck ◽  
Primary Hyperparathyroidism ◽  
Dual Energy ◽  
Mineral Density ◽  
X Ray ◽  
T Score ◽  
Group A ◽  
Group B ◽  
Bone Condition

<p><strong><em>Objective:</em></strong><strong> </strong>Bone loss is a major complication of primary hyperparathyroidism (PHPT), and the extent of bone loss is an important factor for parathyroidectomy. Studies focused on this issue of bone loss in subjects with PHPT are quite rare in our country. This study will help the physicians to take proper action by giving an exact reflection of bone condition in subjects with PHPT. The purpose of this study was to evaluate the bone condition by measuring Bone Mineral Density (BMD), in subjects with PHPT using Dual Energy X-ray Absorptiometry (DEXA) and compare these findings with individuals without PHPT.</p><p><strong><em>Patients and Methods:</em></strong><strong> </strong>It was an analytic cross sectional study (group comparison) carried out at National Institute of Nuclear Medicine and Allied Sciences (NINMAS) BSMMU campus, Dhaka from July 2015-December 2016. Subjects of PHPT diagnosed by biochemical evaluation (increased serum calcium and parathyroid hormone concentrations), between age ranges 15-45 years were selected as group-A. Individuals without biochemical evidence of PHPT or other major illness causing bone loss were selected as comparison group or as group-B. The subjects underwent BMD test by DEXA at lumbar spines from L1-L4 vertebra and the left femoral neck using Norland XR-46 densitometer. BMD was classified according to WHO criteria. Data presented on categorical form were analyzed using chi-squared test. While the data presented on continuous scale were analyzed using student’s t-test. In each analysis, level of significance was 5% and P value &lt;0.05 was considered significant. Data were processed and analyzed with the help of computer software SPSS, version 20.</p><p><strong><em>Results:</em></strong><strong> </strong>Total number of 90 subjects were selected for this study, 45 subjects with PHPT were in group-A and equal number of subjects without PHPT were in group-B. The findings derived from data analysis showed, a significantly more male participants in group-A. The mean age of group-A and group-B was 37.24 ± 8.03 years and 38.20 ± 5.74 years respectively. Mean BMI of group-A was 25.10 ± 4.35 kg/m<sup>2  </sup>in compare to 29.43 ± 5.17 kg/m<sup>2</sup> in group-B. Higher BMI was noted in both groups. PHPT subjects with high BMI had low BMD. BMD expressed in absolute value (gm/cm<sup>2</sup>) and T score. BMD was significantly low in group-A (with PHPT) than in group-B (without PHPT), (p&lt;0.0001). In group-A, prevalence of low BMD was 62.2% (osteopenia 37.8%  and osteoporosis 24.4%)  at lumbar spine and 84.5% (osteopenia 35.6% and osteoporosis 48.9%) at femoral neck. PHPT subjects had significant difference in both T score and BMD between lumbar spine and femoral neck.</p><p><strong><em>Conclusion:</em></strong><strong> </strong>Primary hyperparathyroidism (PHPT) is shown to be associated with significantly reduced BMD especially at femoral neck. Thus, an increased fracture risk should consider if it is left untreated.</p><p>Bangladesh J. Nuclear Med. 20(2): 129-135, July 2017</p>

scholarly journals Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism

2013 ◽  
Vol 169 (2) ◽  
pp. 155-162 ◽  
Author(s):  
Cristina Eller-Vainicher ◽  
Marcello Filopanti ◽  
Serena Palmieri ◽  
Fabio Massimo Ulivieri ◽  
Valentina Morelli ◽  
...  
Keyword(s):  
Primary Hyperparathyroidism ◽  
Trabecular Bone ◽  
Bone Quality ◽  
Trabecular Bone Score ◽  
Dual Energy ◽  
Mineral Density ◽  
Texture Measurement ◽  
X Ray ◽  
Spinal Radiograph ◽  
And Gender

ObjectiveIn primary hyperparathyroidism (PHPT), vertebral fractures (VFx) occur regardless of bone mineral density (BMD) and may depend on decreased bone quality. Trabecular bone score (TBS) is a texture measurement acquired during a spinal dual-energy X-ray absorptiometry (DXA). Recently, TBS has been proposed as an index of bone micro-architecture.DesignWe studied 92 PHPT patients (74 females, age 62.1±9.7 years) and 98 control subjects. In all patients at baseline, in 20 surgically treated patients and in 10 conservatively treated patients after 24 months, TBS, spinal (lumbar spine (LS)) and femoral (total hip (TH) and femoral neck (FN)) BMD were assessed by DXA and VFx by spinal radiograph.ResultsPHPT patients had lower TBS (−2.39±1.8) and higher VFx prevalence (43.5%) than controls (−0.98±1.07 and 8.2% respectively, bothP<0.0001). TBS was associated with VFx (odds ratio 1.4, 95% CI 1.1–1.9,P=0.02), regardless of LS-BMD, age, BMI and gender, and showed a better compromise between sensitivity (75%) and specificity (61.5%) for detecting VFx than LS-BMD, TH-BMD and FN-BMD (31 and 75%, 72 and 44.2%, and 64 and 65% respectively). In surgically treated patients, TBS, LS-BMD, TH-BMD and FN-BMD increased (+47±44.8,+29.2±34.1,+49.4±48.7 and +30.2±39.3% respectively, allP<0.0001). Among patients treated conservatively, TBS decreased significantly in those (n=3) with incident VFx (−1.3±0.3) compared with those without (−0.01±0.9,P=0.048), while BMD changes were not statistically different (LS 0.3±1.2 vs −0.8±0.9 respectively,P=0.19; TH 0.4±0.8 vs −0.8±1.4 respectively,P=0.13 and FN 0.4±0.9 vs −0.8±1.4 respectively,P=0.14).ConclusionsIn PHPT, bone quality, as measured by TBS, is reduced and associated with VFx and improves after surgery.

scholarly journals Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study

2002 ◽  
Vol 87 (10) ◽  
pp. 4482-4489 ◽  
Author(s):  
C. R. Parker ◽  
P. J. Blackwell ◽  
K. J. Fairbairn ◽  
D. J. Hosking
Keyword(s):  
Bone Mineral Density ◽  
Primary Hyperparathyroidism ◽  
Bone Mineral ◽  
Nonvertebral Fracture ◽  
First Year ◽  
Mineral Density ◽  
Short Term ◽  
X Ray ◽  
T Score ◽  
Male Patients

We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism. The treatment group [n = 14; T score ≤ −2.5 sd at the femoral neck (FN) or T ≤ −1.0 sd plus previous nonvertebral fracture] was given alendronate 10 mg/d for 24 months. The second group (n = 18; T score &gt; −2.5 sd at the FN) was untreated. Biochemistry was repeated at 1.5, 3, 6, 12, 18, and 24 months, and dual-energy x-ray absorptiometry at 12 and 24 months. There were no significant between-group baseline differences in calcium, creatinine, or PTH. Alendronate-treated patients gained bone at all sites [lumbar spine (LS), 1 yr gain, +7.3 ± 1.7%; P &lt; 0.001; 2 yr, +7.3 ± 3.1%; P = 0.04). Untreated patients gained bone at the LS over 2 yr (+4.0 ± 1.8%; P = 0.03) but lost bone elsewhere. Calcium fell nonsignificantly in the alendronate group between baseline (2.84 ± 0.12 mmol/liter) and 6 wk (2.76 ± 0.09 mmol/liter), with a nonsignificant rise in PTH (baseline, 103.5 ± 14.6 ng/liter; 6 wk, 116.7 ± 15.6 ng/liter). By 3 months, values had reverted to baseline. In primary hyperparathyroidism, alendronate is well tolerated and significantly improves bone mineral density at the LS (with lesser gains at FN and radius), especially within the first year of treatment. Short-term changes in calcium and PTH resolve by 3 months.

scholarly journals BONE CHANGES IN JAWS AS A RESULT OF PRIMARY HYPERPARATHYROIDISM

2020 ◽  
Vol 23 (2) ◽  
pp. 80-84
Author(s):  
I. V. Kotova ◽  
M. E. Beloshitsky ◽  
V. G. Ignatuk
Keyword(s):  
Primary Hyperparathyroidism ◽  
Bone Structure ◽  
Cortical Layer ◽  
Coarse Grained ◽  
Facial Bones ◽  
Jaw Cysts ◽  
X Ray ◽  
Lower Jaw ◽  
Bone Changes ◽  
Upper Jaw

An analysis of bone changes in the jaws caused by primary hyperparathyroidism (PHPT) was performed based on the research and our own studies. Presented are the modern principles for the diagnosis of PHPT in patients undergoing treatment in maxillofacial clinics with recurrent epulids and jaw cysts. Variously expressed tumor jaw lesions were observed in 23 of 751 patients. 19 of them have the lower jaw, and 4 have the upper jaw tumors. Tumorous masses in 15 patients were caused by parathyroid adenoma, in 7 – by hyperplasia, in 1 – by cancer. The only clinical manifestation of hyperparathyroidism in 5 patients was a tumor-like mass of the upper jaw, in 1 – the lower one. Changes in the bone structure of jaws were found in PHPT patients who underwent orthopantomography, x-ray or computed tomography of the skull. In 26 of them, grainy and coarse-grained bone reconstruction was determined, in 9 – diffuse rarefaction of facial bones, in 10 – focal osteoclasia, in 21 – resorption of the closing plates of the dental alveoli, in 19 – subperiosteal resorption of the cortical layer of lower jaw. It was found that almost impossible to differentiate osteoblastoclastoma and hyperparathyroid osteodystrophy on a pathomorphological basis. In case of detected PHPT, first of all, the operation is performed on the parathyroid glands, and then the treatment strategy for jaw epulids is determined.

Sign in / Sign up

Export Citation Format

Share Document